Laboratory and clinical studies on cefclidin

Yuei Irabu, Hiroshi Fukuhara, Hiroaki Nakamura, Hiroshi Kaneshima, Katsuyoshi Simoji, Keizou Kitsukawa, Yoshiteru Shigeno, Atsushi Saito, Shinko Taira, Isamu Nakasone, Nobuchika Kusano, Seitetsu Hokama, Tsuyoshi Uehara, Kiyoshi Nakao, Syousei Akamine, Hiroyuki Uechi, Masato Yamasiro

Research output: Contribution to journalArticlepeer-review


We performed a laboratory and clinical evaluation of cefclidin (CFCL), a new parenteral cephalosporin, with the following results. 1) Antimicrobial activity The minimum inhibitory concentrations (MICs) of CFCL for a total of 307 clinically isolated strains, were determined and compared with those of Piperacillin, ceftazidime, cefuzonam and ceftizoxime, using MIC2000. CFCL had wide antimicrobial activities to the clinically isolated strains except MSSA, and MRSA. In particular, CFCL had better MICs than another compared antimicrobial agents. 2) Clinical efficacy CFCL 1g/day or 2g/day was given to 6 patients with bacterial pneumonia, 7 patient with chronic bronchitis, 1 patient with bacterial infection complicated with bronchiectasis, and 1 patient with bacterial infection complicated with lung fibrosis, for 4 to 91 days. Clinical responses were excellent in 2 patients, good in 9 patients, fair in 1 patient, not effective in 2 patients, and not evaluated in one patient. Clinical efficacy was 79%. Side effects, including the elevation of intraocular pressure, were not observed in any patients. Elevation of eosinophile was observed in 1 case.

Original languageEnglish
Pages (from-to)396-401
Number of pages6
Publication statusPublished - Sept 1992
Externally publishedYes


  • Cefclidin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology


Dive into the research topics of 'Laboratory and clinical studies on cefclidin'. Together they form a unique fingerprint.

Cite this